Webinar: Targeted Tumor Destruction: High-Throughput Assessment of ADC Cytotoxicity using Flow Cytometry
28 February 2024
08:00 am PT | 11:00 am ET | 17:00 CET | 16:00 GMT
Overview
Antibody-drug conjugates (ADCs) are designed to eliminate cancer cells, by judiciously combining the potency of chemotherapeutic agents with the specificity of monoclonal antibody immunotherapy. The development of efficient in vitro methods to measure the toxic effects of ADCs on cancer cells, is fundamental for accelerating drug development pipelines.
In this webinar, we demonstrate the use of high-throughput flow cytometry in evaluating the efficacy of ADCs which target the HER2 protein on cancer cells. The effectiveness of these ADCs was explored using both traditional 2D monolayer cultures, and intricate 3D tumor spheroids which better mimic the tumor environment in the body.
The webinar will include the following topics:
- Assessing internalization of ADCs into cancer cells, a critical step for their therapeutic effect.
- Evaluating the activation of natural killer cells, through measurement of activation marker expression and cytokine release, providing insight into the antibody-dependent cellular cytotoxicity (ADCC) triggered by the monoclonal antibodies in ADCs.
- Analyzing the diverse ways in which ADCs act on tumor cells, using the distinctive bystander killing effect exhibited by Enhertu® (an anti-HER2 ADC) as an example.
- Live audience Questions and Answers
Webinar Speaker
Kirsty McBain
Sartorius
Kirsty McBain is a Scientist in the BioAnalytics Group of Sartorius, where she is involved in the research and development of novel applications.
Kirsty’s efforts are focused on the iQue® Advanced Flow Cytometry Platform where she has supported a number of the immuno-oncology campaigns that are used to exemplify how Sartorius technology can be applied to the drug discovery process. Kirsty obtained a master’s degree in Biochemistry at the University of Bristol before joining Sartorius in 2019.
